Company
Glycomine
Private, San Carlos, California biotech developing GLM101, a liposomal substrate-replacement therapy for PMM2-CDG, a rare congenital disorder of glycosylation with no approved treatment.
1 story
Regulatory News has published 1 story about Glycomine on 30 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 30 September 2026.
This page is generated from Regulatory News’ editorial coverage of Glycomine. It is not an advertisement.
On the record
- Company
- Glycomine, Inc.
- Headquarters
- San Carlos, California
- Founded
- Around 2014
- Regulator
- U.S. Food and Drug Administration
- Latest milestone
- FDA Breakthrough Therapy Designation, GLM101 for PMM2-CDG
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
